RecruitingNot ApplicableNCT06292286
Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer
Secondary Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer Patients - a Pilot Study
Sponsor
The University of Hong Kong
Enrollment
18 participants
Start Date
Nov 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection. Whether secondary interval surgery can be used at recurrence is not known.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria6
- Histologically diagnosed EOC, fallopian tube or primary peritoneal carcinoma
- \>= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and / or PARPi, at primary setting
- Platinum-free interval should be \>=6 months from the last dose of platinum-based chemotherapy
- Upfront SCR not feasible
- Patients should have Eastern Cooperative Oncology Group (ECOG) performance score 0 to 2 within 28 days prior to recruitment.
- Patients must have adequate bone marrow, renal, hepatic and neurological function within 28 days prior to the start of treatment.
Exclusion Criteria6
- Non-epithelial or borderline tumors are excluded
- Patients who have with concurrent malignancy within five years (except for basal or squamous cell skin cancer, in-situ breast cancer, stage 1a grade 1-2 endometrioid endometrial carcinoma without lymphovascular invasion) are excluded.
- Patients using more than one line of chemotherapy are excluded.
- Patients who have platinum-resistant or refractory recurrence are excluded.
- Patients having second relapse or beyond are excluded.
- Patients who have contraindications to operation, e.g., unresolved thrombocytopenia, bowel obstruction in the last 4 weeks prior to enrolment
Interventions
PROCEDURECarboplatin or cisplatin
Carboplatin of cisplatin for 3-6 cycles
DRUGPaclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar
Paclitaxel, gemcitabine or liposomal doxorubicin, for 3-6 cycles
DRUGBevacizumab or biosimilar
Optional
PROCEDURECytoreductive surgery
Cytoreductive surgery after chemotherapy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06292286
Related Trials
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT05554328296 locations
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377475 locations
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT045504944 locations
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
NCT064830481 location
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT052311222 locations